Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022


  • Published On : Jun-2015 |
  • Pages : 106 Pages |
  • Format :

Next-generation antibody therapeutics refer to the improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Next-generation antibody-based therapeutics overcome the limitations of monoclonal antibodies and feature enhancements to existing properties of therapeutic antibodies. Various biotechnology and biopharmaceutical companies are actively involved in development of next-generation antibody therapeutics, especially for cancer, autoimmune, and inflammatory diseases. Factors such as growing R&D activities, increasing prevalence of chronic diseases, technological advancements in antibody therapeutics, and rising healthcare expenditure are driving growth of the global next-generation antibody therapeutics market. However, stringent regulatory requirements, long approval times for new drugs, and high costs of next-generation antibody therapeutics are some of the key restraints for growth of the market.

North America is the largest market for next-generation antibody therapeutics. The U.S. represents the largest market for next-generation antibody therapeutics in the region. This is due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing R&D activities in the country.

This report provides in-depth analysis and estimation of the global next-generation antibody therapeutics market for the period 2015–2022, considering 2014 as the base year for calculations. In addition, data pertaining to current market dynamics, including market drivers, restraints, and strategic developments has been provided in the report. The next-generation antibody therapeutics market is categorized on the basis of technology, therapeutic application, and geography. Based on technology, the next-generation antibody therapeutics market is segmented into antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. In terms of therapeutic application, the market is segmented into oncology and autoimmune/inflammatory diseases. In the geographical analysis, the report identifies and analyzes market size and forecast for North America, Europe, Asia, and Rest of the World (RoW).

Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare expenditure is also driving growth of the global next-generation antibody therapeutics market. However, factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements, and long approval time are restraining growth of the market. The global next-generation antibody therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022.

North America is the largest market for next-generation antibody therapeutics. In terms of technology, antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics market. On the basis of therapeutic application, oncology dominates the next-generation antibody therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the increasing use of ADC technology.

Various biotechnology and biopharmaceutical companies are actively involved in development and manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen, Inc., Biogen, Bayer AG, and Xencor, Inc.

next-generation-antibody-therapeutics-market

Some of the major players in the market:

  • F. Hoffmann-La Roche Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Seattle Genetics, Inc.
  • ImmunoGen, Inc.
  • Amgen, Inc.
  • Biogen.
  • Bayer AG.
  • Xencor, Inc.
  • Other.

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.

Chapter 1 Preface 10

1.1 Report Description 10

1.2 Research Methodology 11

1.3 Assumptions 11

Chapter 2 Market Synopsis 12

Chapter 3 Porter’s Five Forces Analysis 14

3.1 Bargaining Power of Suppliers 14

3.2 Bargaining Power of Buyers 14

3.3 Threat of New Entrants 14

3.4 Threat of Substitutes 14

3.5 Intensity of Rivalry 14

Chapter 4 Industry Overview 15

4.1 Market Definition 15

4.2 Market Drivers 17

      4.2.1 Growing R&D activities 17

      4.2.2 Increasing prevalence of chronic diseases 18

      4.2.3 Technological advancements in antibody therapeutics 18

      4.2.4 Increasing healthcare expenditure 19

4.3 Impact Analysis of Market Drivers 20

4.4 Restraints 22

      4.4.1 Stringent regulatory requirements and long approval times for new drugs 22

      4.4.2 High costs of next-generation antibody therapeutics 23

4.5 Impact Analysis of Market Restraints 24

4.6 Market Trends 24

      4.6.1 Increasing usage of antibody-drug conjugates (ADC) technology is gaining popularity in next-generation antibody therapeutics market 24

      4.6.2 Rising number of collaborations for development of next-generation antibody therapeutics 25

Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs 28

Chapter 6 Global Market Size and Forecast 33

6.1 On the Basis of Geography 33

6.2 On the Basis of Therapeutic Area 34

6.3 On the Basis of Technology 36

Chapter 7 Market Size and Forecast by Therapeutic Area 38

7.1 Oncology 38

7.2 Autoimmune/Inflammatory 40

Chapter 8 Market Size and Forecast by Technology 42

8.1 Antibody-drug conjugates (ADCs) 42

8.2 Bispecific antibodies 44

8.3 Fc engineered antibodies 46

8.4 Antibody fragments and antibody-like proteins 48

8.5 Biosimilar antibody products 51

Chapter 9 Market Size and Forecast by Geography 53

9.1 North America 53

9.2 Europe 56

9.3 Asia 61

9.4 Rest of the World 64

Chapter 10 Competitive Scenario 65

10.1 Competitive Benchmarking 65

10.2 Company Share Analysis 67

Chapter 11 Company Profiles 69

11.1 F. Hoffmann-La Roche Ltd 69

      11.1.1 Company Overview 69

      11.1.2 Products and services 70

      11.1.3 Financial performance 71

      11.1.4 Key Developments 71

11.2 Kyowa Hakko Kirin Co., Ltd. 73

      11.2.1 Company Overview 73

      11.2.2 Products and Services 74

      11.2.3 Financial performance 75

      11.2.4 Key Developments 75

11.3 Seattle Genetics, Inc. 77

      11.3.1 Company Overview 77

      11.3.2 Products and Services 77

      11.3.3 Financial performance 78

      11.3.4 Key Developments 78

11.4 ImmunoGen, Inc. 80

      11.4.1 Company Overview 80

      11.4.2 Products and Services 80

      11.4.3 Financial performance 81

      11.4.4 Key Developments 81

11.5 Bristol-Myers Squibb Company 83

      11.5.1 Company Overview 83

      11.5.2 Products and Services 83

      11.5.3 Financial performance 84

      11.5.4 Key Developments 84

11.6 Pfizer, Inc. 87

      11.6.1 Company Overview 87

      11.6.2 Products and Services 87

      11.6.3 Financial performance 88

      11.6.4 Key Developments 88

11.7 Amgen, Inc. 90

      11.7.1 Company Overview 90

      11.7.2 Products and Services 90

      11.7.3 Financial performance 91

      11.7.4 Key Developments 91

11.8 Biogen 93

      11.8.1 Company Overview 93

      11.8.2 Products and Services 93

      11.8.3 Financial performance 94

      11.8.4 Key Developments 94

11.9 Bayer AG 95

      11.9.1 Company Overview 95

      11.9.2 Products and Services 95

      11.9.3 Financial performance 96

      11.9.4 Key Developments 96

11.10 Xencor, Inc. 97

      11.10.1 Company Overview 97

      11.10.2 Products and Services 97

      11.10.3 Financial performance 98

      11.10.4 Key Developments 98

11.11 Takeda Pharmaceuticals Company Limited 99

      11.11.1 Company Overview 99

      11.11.2 Products and services 99

      11.11.3 Financial performance 100

      11.11.4 Key Developments 101

11.12 AstraZeneca 102

      11.12.1 Company Overview 102

      11.12.2 Products and Services 102

      11.12.3 Financial performance 103

      11.12.4 Key Developments 103

11.13 Dyax Corp. 105

      11.13.1 Company Overview 105

      11.13.2 Products and Services 105

      11.13.3 Financial performance 106

      11.13.4 Key Developments 106


List of Tables

TABLE 1 Market snapshot: Next-generation antibody therapeutics market, 2015 and 2022 12

TABLE 1 Drivers for next-generation antibody therapeutics market: Impact analysis 20

TABLE 2 Estimated average timelines for clinical trial approval in various countries 22

TABLE 3 Restraints for next-generation antibody therapeutics market: Impact analysis 24

TABLE 4 Major collaborations in next-generation antibody therapeutics market (2012- April 2015) 26

TABLE 6 Global next-generation antibody therapeutics market size, by region, 2010 – 2013 (US$ Mn) 33

TABLE 7 Global next-generation antibody therapeutics market size, by region, 2014 – 2020 (US$ Mn) 34

TABLE 8 Global next-generation antibody therapeutics market size, by therapeutic area, 2010 – 2013 (US$ Mn) 35

TABLE 9 Global next-generation antibody therapeutics market size, by application, 2014 – 2020 (US$ Mn) 35

TABLE 10 Global next-generation antibody therapeutics market size, by technology, 2010 – 2013 (US$ Mn) 37

TABLE 11 Global next-generation antibody therapeutics market size, by technology, 2014 – 2020 (US$ Mn) 37

TABLE 12 Global oncology next-generation Ab therapeutics market size, by region, 2010 – 2013 (US$ Mn) 39

TABLE 13 Global oncology next-generation Ab therapeutics market size, by region, 2014 – 2020 (US$ Mn) 39

TABLE 14 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2010 – 2013 (US$ Mn) 40

TABLE 15 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2014 – 2020 (US$ Mn) 41

TABLE 16 Global ADCs market size, by region, 2010 – 2013 (US$ Mn) 43

TABLE 17 Global ADCs market size, by region, 2014 – 2020 (US$ Mn) 43

TABLE 18 Global BsAbs market size, by region, 2010 – 2013 (US$ Mn) 44

TABLE 19 Global BsAbs market size, by region, 2014 – 2020 (US$ Mn) 45

TABLE 20 Global Fc engineered antibodies market size, by region, 2010 – 2013 (US$ Mn) 47

TABLE 21 Global Fc engineered antibodies market size, by region, 2014 – 2020 (US$ Mn) 47

TABLE 22 Global antibody fragments and antibody-like proteins market size, by region, 2010 – 2013 (US$ Mn) 49

TABLE 23 Global antibody fragments and antibody-like proteins market size, by region, 2014 – 2020 (US$ Mn) 49

TABLE 24 Global biosimilar antibody products market size, by region, 2010 – 2013 (US$ Mn) 52

TABLE 25 Global biosimilar antibody products market size, by region, 2014 – 2020 (US$ Mn) 52

TABLE 26 North America next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn) 54

TABLE 27 North America next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn) 54

TABLE 28 Europe next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn) 59

TABLE 29 Europe next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn) 60

TABLE 30 Asia next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn) 62

TABLE 31 Asia next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn) 63

TABLE 32 Major product categories of Roche 70

TABLE 33 Major product segments of Kyowa Hakko Kirin Co., Ltd. 74

TABLE 34 Major product categories of Seattle Genetics, Inc. 77

TABLE 35 Product category of ImmunoGen, Inc. 80

TABLE 36 Major product segments of Bristol-Myers Squibb Company 83

TABLE 37 Major product segments of Pfizer, Inc. 87

TABLE 38 Major product categories of Amgen 90

TABLE 39 Major categories of therapies of Biogen 93

TABLE 40 Major product categories of Bayer AG 95

TABLE 41 Product category of Xencor 97

TABLE 42 Major product categories of Takeda 100

TABLE 43 Major product categories of AstraZeneca 102

TABLE 44 Product category of Dyax Corp. 105


List of Figures 

FIG. 1 Next-generation antibody therapeutics market: Porter’s five force analysis 14

FIG. 2 Health expenditure as total percentage of GDP, 2002 and 2012 20

FIG. 3 Global next-generation antibody therapeutics market share, by region, by value, 2013 33

FIG. 4 Global next-generation antibody therapeutics market share, by therapeutic area, by value, 2013 34

FIG. 5 Global next-generation antibody therapeutics market share, by technology, by value, 2013 36

FIG. 6 Global oncology next-generation Ab therapeutics market share, by region, by value, 2013 38

FIG. 7 Global autoimmune/inflammatory next-generation Ab therapeutics market share, by region, by value, 2013 40

FIG. 8 Global ADCs market share, by region, by value, 2013 42

FIG. 9 Global BsAbs market share, by region, by value, 2013 44

FIG. 10 Global Fc engineered antibodies market share, by region, by value, 2013 46

FIG. 11 Global antibody fragments and antibody-like proteins market share, by region, by value, 2013 48

FIG. 12 Global biosimilar antibody products market share, by region, by value, 2013 51

FIG. 13 North America next-generation antibody therapeutics market share, by country, by value, 2013 54

FIG. 16 Europe next-generation antibody therapeutics market share, by country, by value, 2013 59

FIG. 17 Asia next-generation antibody therapeutics market share, by country, by value, 2013 62

FIG. 18 Competitive benchmarking of next-generation antibody therapeutics 65

FIG. 19 Global next-generation antibody therapeutics market, by company 2014 (% share) 67

FIG. 20 Sales and net income of Roche, 2012 – 2014 (US$ Mn) 71

FIG. 21 Net sales and net income of Kyowa Hakko Kirin Co., Ltd., 2012 – 2014 (US$ Mn) 75

FIG. 22 Total revenue and net loss of Seattle Genetics, Inc., 2012 – 2014 (US$ Mn) 78

FIG. 23 Total revenue and net loss of ImmunoGen, Inc., 2012 – 2014 (US$ Mn) 81

FIG. 24 Total revenue and net earnings of Bristol-Myers Squibb Company, 2012 – 2014 (US$ Mn) 84

FIG. 25 Revenue and net income of Pfizer, Inc., 2012 – 2014 (US$ Mn) 88

FIG. 26 Revenue and net income of Amgen, 2012 – 2014 (US$ Mn) 91

FIG. 27 Total revenue and net income of Biogen, 2012 – 2014 (US$ Mn) 94

FIG. 28 Net sales and net income of Bayer AG, 2012 – 2014 (US$ Mn) 96

FIG. 29 Revenues and net loss of Xencor, 2012 – 2014 (US$ Mn) 98

FIG. 30 Revenue and net profit of Takeda, 2012 – 2014 (US$ Mn) 100

FIG. 31 Revenue and profit of AstraZeneca, 2012 – 2014 (US$ Mn) 103

FIG. 32 Total revenue and net loss of Dyax Corp., 2012 – 2014 (US$ Mn) 106

Back To Top